Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_assertion type Assertion NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_head.
- NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_provenance.
- NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_assertion evidence source_evidence_literature NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_provenance.
- NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_assertion SIO_000772 18843116 NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_provenance.
- NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_assertion wasDerivedFrom befree-20140225 NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_provenance.
- NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_assertion wasGeneratedBy ECO_0000203 NP270380.RAXnQidLdng-rwU6G9HtSUfXksZL67HOY0QRpc7_8OYhU130_provenance.